CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study

Blood Advances · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles